Want to join the conversation?
$AGN and $ADMS announced U.S. availability of new dosage strengths for Namzaric (Memantine and Donepezil Hydrochlorides) extended release for the treatment of moderate to severe Alzheimer's disease. Namzaric's new indication and dosage strengths were approved by the FDA in July 2016.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.